Quantcast

Industry news that matters to you.  Learn more

Archives for June 2011

DHMRI Establishes Immune Monitoring Laboratory for Biomarker Discovery and Development

Last week, the David H. Murdock Research Institute (DHMRI) announced that it acquired the Immune Tolerance Institute, Inc. (ITI) as a next step in its continued growth. The DHMRI provides integrated, state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms as a major resource for a range of academic and industry partners undertaking both preclinical and clinical research.

NINDS to Fund Biomarker Clinical Study for Spinal Muscular Atrophy

SMA is associated with a mutation in chromosome 5 — loss of the survival of motor neuron 1 gene (SMN1) — and is considered the second most common autosomal recessive disease in the US, affecting 1 in 6000 live births. SMA Type 1 is one of the most common genetic causes of infantile death. Although the disease can be readily diagnosed, there are no approved treatments for SMA.

ResearchDx and CompanDX Announce Strategic Partnership

ResearchDx, LLC of Irvine, California yesterday announced a strategic partnership with CompanDX of Nottingham UK. ResearchDx and CompanDX have forged a unique partnership to offer a full capability to discover and deliver novel molecular diagnostic tests for clients in the healthcare setting. CompanDX uses its unique “Distiller” platform to deliver small composite biomarker signatures from complex data of high dimensionality, which are commonplace in clinical development of therapeutics. ResearchDx draws on its broad capability to design, produce and validate tests ready for the market and represents a new breed of service provider, the first CDO to offer turnkey solutions for companion diagnostic delivery.

Qiagen Makes Proposal to Fully Acquire Ipsogen, Further Expanding Leadership in Oncology Molecular Diagnostics

Qiagen N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological (blood) cancers.

George Washington University Researchers Receive NCI Award to Study Cancer from a Neglected Tropical Disease

Researchers from The George Washington University School of Medicine and Health Sciences (SMHS) have been awarded a five-year, $500,000-per-year R01 grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). This award will support investigations by SMHS researchers who are developing proteomic biomarkers for Opisthorchis-induced bile duct cancer. The liver fluke Opisthorchis viverrini is a food-borne parasite that currently infects more than 40 million people, primarily in the Southeast Asian countries of Thailand, Laos, and Cambodia, where uncooked fish, intermediate hosts for O. viverrini, are a staple of the diet. O. viverrini is considered among the most important of the food-borne trematodes due to its strong association with bile duct fibrosis and bile duct cancer (cholangiocarcinoma) as determined by the World Health Organization’s International Agency for Research on Cancer (IARC). IARC categorizes this parasitic worm as a Group 1 carcinogen – a definitive cause of cancer.